TransMedics Group, Inc. Form 8-K Summary
Business Context and Reporting Period
TransMedics Group, Inc. filed this Current Report on Form 8-K on May 28, 2021, reporting matters voted on at its May 27, 2021 annual meeting of shareholders. The filing concerns corporate governance and auditor ratification rather than operating or financial results.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial performance metrics.
Material Changes Versus Prior Comparable Period
No material period-over-period financial or operating changes are reported.
Governance, Outlook, and Other Matters
- Shareholders elected Waleed H. Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines, and David Weill, M.D. as directors, each to serve until the 2022 annual meeting or until a successor is elected and qualified, or earlier departure.
- All eight director nominees were elected. Votes included 4,550,143 broker non-votes for each nominee; the number of votes for each nominee ranged from 11,757,724 to 15,293,682.
- Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021. The vote was 19,751,586 for, 110,283 against, and 2,163 abstentions.
- The filing contains no management guidance, outlook, risk update, contingency, financing announcement, or unusual financial item.
Investor Verification Items
- Verify the composition and independence of the board following the director elections.
- Review subsequent filings for any changes to the board, auditor, or committee assignments.
- Consult the company’s quarterly and annual filings for financial results, liquidity, debt, risks, and operating outlook, which are not included in this Form 8-K.